Alexander Melerzanov Presented Russian Innovations in Cognitive Longevity, Rehabilitation, and Healthy Nutrition to State Duma Deputy Fedot Tumusov
On February 26, Alexander Melerzanov, the Deputy Executive Director of the Institute of Biophysics of the Future at Moscow Institute of Physics and Technology (MIPT), Associate Professor of the Department of Innovative Pharmacy, Medical Technology, and Biotechnology, Ph.D., and Head of the FBA EAC Committee on Science and Education, held a strategic meeting with Fedot Tumusov, First Deputy Chairman of the State Duma Committee on Health, Doctor of Economics, Professor, and Deputy of the State Duma of the Russian Federation.
The discussion centered on advanced Russian developments in the domains of cognitive health, medical rehabilitation, and healthy nutrition. During this meeting, Alexander Melerzanov presented a comprehensive array of technologies designed to address a broad spectrum of challenges, including the mitigation of age-related cognitive decline and the rehabilitation of patients following severe illnesses and injuries. A particular focus was placed on the indigenous Russian origin of the equipment and technologies presented.
Terms of participation
System-wide magnetic therapy using the Magnetoturbotron device represents a unique medical apparatus, which lacks analogues and is designed to simultaneously influence all body systems through a vortex magnetic field. This device provides a fundamental basis for maintaining cognitive health by normalizing hemodynamics, microcirculation, and suppressing chronic inflammation, which are key factors in the aging process and cognitive decline.
Gamma sensory stimulation at 40 Hz is a Russian prototype device for inducing gamma rhythms in the brain, which is nearly ready for technical testing. The method, founded on leading global research conducted by the Massachusetts Institute of Technology (MIT) in the United States and the Kunming Institute of Zoology, employs unique exposure techniques to elicit a heightened brain response to stimulation. This technology demonstrates promising outcomes in mitigating the progression of Alzheimer's disease, as evidenced by magnetic resonance imaging (MRI) scans indicating a reduction in hippocampal atrophy and cognitive assessments showing stabilization of memory and daily functional abilities. A significant advantage is the absence of adverse effects such as edema and microbleeds, which are characteristic of certain pharmacological interventions.
The NeuroOptima device, utilizing audio-visual alpha stimulation, represents an innovative technology developed over the past 25 years through extensive scientific research conducted by the Institute of Cell Biophysics of the Russian Academy of Sciences in collaboration with Lobachevsky University. This device implements a dual-module biofeedback system that monitors and regulates both brain electrical activity and cardiac rhythm, without requiring the patient to consciously acquire self-regulation skills. The device is designed to adapt autonomously to the individual's physiological parameters. Exposure to light and sound stimuli at an alpha rhythm frequency of 8-13 Hz synchronizes brain activity, as evidenced by clinical trials. The efficacy of this method ranges from 75% to 100%, depending on the specific nosology, with notable reductions in anxiety levels (up to 30%) and significant improvements in quality of life. The device is indicated for the treatment of chronic fatigue syndrome, post-stroke effects, post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), and age-related cognitive decline.
The NeureX device is designed for the selective activation of the brain's median structures, specifically the hypothalamic-pituitary system, through the application of a low-intensity electrical signal. Post-initial treatment, there is observed normalization of cortisol and somatotropic hormone levels, which is attributed to the initiation of an "emergency adaptation" response. The device demonstrates a broad spectrum of effects, including anti-stress, analgesic, anti-inflammatory, immunomodulatory, and drug-enhancing properties. Its compact and portable design facilitates both outpatient and home-based use.
The Sweet Protein project, a geroprotective formulation comprising amino acids and a prebiotic, received special attention. On December 17, 2025, the Committee on Science and Education of FBA EAC held its inaugural practical session dedicated to this development. The product was developed by young scientists and underwent a double-blind study to evaluate its organoleptic properties. It is marketed as a healthy alternative to sugar, intended for individuals with diabetes and applicable in dietary and sports nutrition sectors.
Fedot Tumusov commended the potential of the presented equipment, highlighting its utility in medical rehabilitation and the rehabilitation of Special Military Operation veterans. The technologies are effective for the management of post-traumatic stress disorder (PTSD) using "NeuroOptima," recovery from severe injuries with "Magnetoturbotron" and NeureX, and stress mitigation. Additionally, the "sweet protein" is proposed to enhance the quality of life for individuals with metabolic disorders such as diabetes and obesity.
The meeting underscored the significant potential of Russian scientific advancements in addressing governmental priorities, ranging from improving the quality of life for elderly populations to supporting the health of national defense personnel.
To facilitate public discussion on the integration of innovative medical technologies into healthcare practice, Fedot Tumusov extended an invitation to Alexander Melerzanov to present an online lecture at the roundtable "Modern Issues of Equipment, Maintenance, and Operation of Medical Devices in Medical Institutions of the Russian Federation and the Republic of Sakha (Yakutia)." The event is organized by the State Duma Committee on Health Protection and is scheduled for March 3 in Yakutsk.